Women's health

KIDRON Capital Assets Announces First Close of Women's Health VC Fund

Retrieved on: 
Tuesday, April 9, 2024
Health, CE, Significance, Partnership, Risk, AKI, Female, Acute kidney injury, Cancer, Medtronic, Quality of life, Woman, Women's health, Investment, Safety, Future, Therapy, TEL

TEL AVIV, Israel, April 9, 2024 /PRNewswire/ -- We are thrilled to announce the successful first close of KIDRON Capital Assets, marking a significant milestone as the premier venture capital fund dedicated to Women's Health. Led by two female General Partners with profound investment and industry expertise in the HealthTech sector, KIDRON is uniquely positioned at the intersection of groundbreaking healthcare innovation and untapped investment potential. Our primary mission is to generate superb returns for our investors by capitalizing on the extensive, yet often overlooked, opportunities within the women's health sector.

Key Points: 
  • TEL AVIV, Israel, April 9, 2024 /PRNewswire/ -- We are thrilled to announce the successful first close of KIDRON Capital Assets, marking a significant milestone as the premier venture capital fund dedicated to Women's Health.
  • Our primary mission is to generate superb returns for our investors by capitalizing on the extensive, yet often overlooked, opportunities within the women's health sector.
  • KIDRON's portfolio encompasses a diverse array of sectors, including medical devices, diagnostics, digital health, therapeutics, and services.
  • Invest in the Future of Women's Health: Partner with KIDRON Capital to Generate High Returns and Make a Difference.

KIDRON Capital Assets Announces First Close of Women's Health VC Fund

Retrieved on: 
Tuesday, April 9, 2024
Health, CE, Significance, Partnership, Risk, AKI, Female, Acute kidney injury, Cancer, Medtronic, Quality of life, Woman, Women's health, Investment, Safety, Future, Therapy, TEL

TEL AVIV, Israel, April 9, 2024 /PRNewswire/ -- We are thrilled to announce the successful first close of KIDRON Capital Assets, marking a significant milestone as the premier venture capital fund dedicated to Women's Health. Led by two female General Partners with profound investment and industry expertise in the HealthTech sector, KIDRON is uniquely positioned at the intersection of groundbreaking healthcare innovation and untapped investment potential. Our primary mission is to generate superb returns for our investors by capitalizing on the extensive, yet often overlooked, opportunities within the women's health sector.

Key Points: 
  • TEL AVIV, Israel, April 9, 2024 /PRNewswire/ -- We are thrilled to announce the successful first close of KIDRON Capital Assets, marking a significant milestone as the premier venture capital fund dedicated to Women's Health.
  • Our primary mission is to generate superb returns for our investors by capitalizing on the extensive, yet often overlooked, opportunities within the women's health sector.
  • KIDRON's portfolio encompasses a diverse array of sectors, including medical devices, diagnostics, digital health, therapeutics, and services.
  • Invest in the Future of Women's Health: Partner with KIDRON Capital to Generate High Returns and Make a Difference.

Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer

Retrieved on: 
Monday, March 18, 2024
Neurology, University of Pennsylvania, Sarcoma, Cardiology, Ivy League, Protocol, University, Rheumatology, Dermatology, Infection, Harvard University, FSD, Melanoma, CMO, Vaccine, FDA, GU, Women's health, Yale University, Pharmaceutical industry

MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Dr. Huma Qamar as Chief Medical Officer (CMO).

Key Points: 
  • MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Dr. Huma Qamar as Chief Medical Officer (CMO).
  • “I’m very pleased to name Dr. Qamar as the CMO at Ocugen,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen.
  • Her expertise encompasses the development of Phase I-IV clinical protocols and execution of clinical studies, FDA inspections, and effective leadership of medical affairs teams.
  • “Dr.

Tunde Oyeneyin — Instant New York Times Best-selling Author, Peloton Instructor, Nike Athlete and Change Maker — to Keynote IAMPHENOM 2024

Retrieved on: 
Monday, March 25, 2024
Women, Other Technology, Software, Human Resources, Artificial Intelligence, Internet, Consumer, Professional Services, Technology, General Sports, General Health, Sports, Marketing, Health, Other Education, Communications, Training, Education, Automation, Conference, Growth, Intelligence, Empathy, Access Hollywood, Good Morning America, Human voice, Women's health, Multimedia, SHRM

Phenom today announced Tunde Oyeneyin as a keynote speaker at IAMPHENOM — the human resources conference for hiring, developing and retaining talent taking place April 23-25 in Philadelphia.

Key Points: 
  • Phenom today announced Tunde Oyeneyin as a keynote speaker at IAMPHENOM — the human resources conference for hiring, developing and retaining talent taking place April 23-25 in Philadelphia.
  • View the full release here: https://www.businesswire.com/news/home/20240325637971/en/
    Tunde Oyeneyin, the instant New York Times best-selling author, Peloton instructor, Nike Athlete and change maker, will keynote IAMPHENOM, the human resources conference for hiring, developing and retaining talent taking place April 23-25 in Philadelphia.
  • (Photo: Business Wire)
    Known worldwide as an instant New York Times best-selling author, electric and charismatic Peloton instructor, Nike Athlete and change maker, Tunde brings her unparalleled positive energy to inspire audiences.
  • Tunde has recently been featured for her powerful work on The TODAY SHOW, Good Morning America, Access Live, The New York Times, Vogue, Women's Health and more.

Aegis Ventures Announces Partnership with Nine Health Systems to Build and Deploy Healthtech Solutions

Retrieved on: 
Tuesday, April 2, 2024
Stanford University Medical Center, Automation, Ohio State University, Indiana University Health, Health, Partnership, Patient, Mayo Clinic, Record, Consortium, Northwell Health, Novant Health, Ecosystem, Sharp HealthCare, Memorial Hermann Health System, Women's health

NEW YORK, April 2, 2024 /PRNewswire/ -- Today, Aegis Ventures, a New York-based venture studio, welcomed nine leading health systems as founding members of the Digital Consortium. These health systems will innovate directly with Aegis to co-develop, invest in, and deploy healthtech solutions that address healthcare's most pressing quality, equity, and cost problems, and enable them to better care for the communities they serve, while generating diversified sources of revenue.

Key Points: 
  • The health systems collaborating with Aegis include: Endeavor Health, Indiana University Health, Memorial Hermann Health System, Northwell Health, Novant Health, Ochsner Health, The Ohio State University Wexner Medical Center, Sharp HealthCare, and Stanford Health Care.
  • Since its launch in 2020, Aegis Ventures has established a novel approach to how entrepreneurs and health systems collaborate to build and deploy new technologies that improve access, affordability, quality, and sustainability.
  • The Digital Consortium harnesses health systems' collective expertise to foster groundbreaking solutions, redefining healthcare delivery for the better," said Michael Dowling, President and CEO of Northwell Health.
  • "The partnership between Aegis Ventures and Northwell Health epitomizes the transformative impact that new technologies can have on health system patients and employees," said Aegis Ventures Co-Founder and Managing Partner John Beadle.

MysteryVibe partners with Havas Lynx and makes history by showcasing the very first sex toy on billboards in the U.S.

Retrieved on: 
Monday, March 25, 2024
Lynx, Lubrication, FSA, Health, Partnership, Genetics, SVP, Libido, MysteryVibe, History, Menopause, Masturbation, Fertility, Atrophy, Woman, Pleasure, Women's History Month, Sensation, OOH, Stigma, Orgasm, Personal lubricant, HSA, FDA, Women's health, Birth control

The billboard is the first of its kind, making history in sexual wellness advertising by showcasing a visible sex toy in Central Manhattan.

Key Points: 
  • The billboard is the first of its kind, making history in sexual wellness advertising by showcasing a visible sex toy in Central Manhattan.
  • "We are incredibly lucky to have been a part of many 'firsts' in women's health over the past decade," shared Soumyadip Rakshit, CEO and cofounder, MysteryVibe.
  • "Not only are we honored to support a campaign that enables women to overcome taboos around menopause, we know that discomfort shouldn't be normalized."
  • In conjunction with the billboard, the campaign contains other educational elements backed by award-winning reproductive scientist Professor Joyce Harper .

Doctor's BiomeⓇ: Women's Health - Dietary Supplement Inhibited Pathogenic E. coli Bacteria and C. albicans Yeast

Retrieved on: 
Thursday, March 21, 2024
Food science, Urinary tract infection, Growth, Nutrition, Vaginal discharge, Health, Pelvic pain, Common, Journal, Candidiasis, UTI, Chills, Escherichia coli, Woman, Women's health, Infection, Fever, Urinary incontinence, Pain, Dietary supplement

Common UTI symptoms include urge and urinary incontinence, burning sensation while urinating, cloudy urine and pelvic pain.

Key Points: 
  • Common UTI symptoms include urge and urinary incontinence, burning sensation while urinating, cloudy urine and pelvic pain.
  • "Doctor's BiomeⓇ: Women's Health, is the first successful line extension of Doctor's BiomeⓇ.
  • Dr. Howard F. Robins, Chief Medical Officer of Doctor's BiomeⓇ explained "Our focus was to develop a proprietary dietary supplement for women that can inhibit both E. coli and C.
  • To develop Women's Health dietary supplement, we used Doctor's BiomeⓇ proprietary blend of five strains of Bifidobacteria and ten strains of Lactobacilli, as well as organic cranberry powder.

Dr. Ava Shamban Joins MedSpa Partners

Retrieved on: 
Wednesday, March 13, 2024
Vanity Fair, Beauty, Patient, Rest, Dermatology, Publication, Good Morning America, Women's health, Principal investigator, AVA, MSP, Extreme Makeover, Health, Television, Medical device

TORONTO, March 13, 2024 /PRNewswire/ - MedSpa Partners Inc. ("MSP") is proud to welcome Dr. Ava Shamban and her team at Ava MD to its top-tier North American medical aesthetics platform.

Key Points: 
  • TORONTO, March 13, 2024 /PRNewswire/ - MedSpa Partners Inc. ("MSP") is proud to welcome Dr. Ava Shamban and her team at Ava MD to its top-tier North American medical aesthetics platform.
  • Speaking on her reasons for joining MedSpa Partners, Dr. Shamban shared, "Like many of my colleagues, I was approached by numerous groups looking to acquire my practices.
  • MSP CEO Dominic Mazzone commented, "While Los Angeles can be associated with some of the more extreme approaches to cosmetic medicine, Ava Shamban is an icon for the kind of natural, individualized, and responsible medical aesthetics that MedSpa Partners promotes.
  • We couldn't be more excited to welcome Dr. Shamban and the exceptional team at Ava MD to MedSpa Partners."

Cedar Health Research Launches Two New Clinical Research Sites in Texas

Retrieved on: 
Wednesday, March 13, 2024
United States Census Bureau, Health, Internal medicine, Neurology, DSM-IV codes, CHR, Partnership, Patient, Research, Clinical trial, Vaccine, Endocrinology, Women's health, Pharmaceutical industry

DALLAS, March 13, 2024 /PRNewswire/ -- Today, Cedar Health Research®, a multi-therapeutic independent clinical research site and patient network, officially announced two new sites in Texas located in Arlington, TX and Midland, TX.

Key Points: 
  • DALLAS, March 13, 2024 /PRNewswire/ -- Today, Cedar Health Research®, a multi-therapeutic independent clinical research site and patient network, officially announced two new sites in Texas located in Arlington, TX and Midland, TX.
  • Cedar Health Research expands independent clinical research site and patient network with Arlington and Midland sites.
  • The Arlington site will now serve as the Tarrant County mid-cities hub location for Cedar Health Research's (CHR) Dallas-Fort Worth clinical operations.
  • "When Cedar Health Research launched in 2020, we pursued the mission of expanding clinical trial access to the diverse communities of Texas through our unique technology enabled healthcare partnership model.

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the F

Retrieved on: 
Tuesday, February 27, 2024
Acquisition, Breast cancer, Neoplasm, Cancer, SSO, Forecasting, MD, ASCO, Growth, GM, American College of Neuropsychopharmacology, Surgical oncology, Myriad Genetics, Society, Capital expenditure, GAAP, Genetics, American College, Health, Patient, Public expenditure, Women's health, MCRR, IPG, Video game

SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its fourth quarter and full-year ended December 31, 2023 and provided its outlook on business performance for its first quarter and full-year 2024.

Key Points: 
  • GAAP operating expenses in the fourth quarter of 2023 were $166.4 million, decreasing $9.7 million year-over-year.
  • Adjusted operating expenses in the fourth quarter of 2023 decreased $8.6 million year-over-year to $130.0 million, reflecting incremental cost control measures during the fourth quarter 2023.
  • GAAP operating loss in the fourth quarter of 2023 was $31.4 million, improving $20.8 million year-over-year; adjusted operating income in the fourth quarter of 2023 was $5.7 million, improving $19.6 million year-over-year from adjusted operating loss of $13.9 million in the fourth quarter of 2022.
  • Fourth quarter 2023 GAAP cash flow from operations was $(55) million; adjusted cash flow from operations in the fourth quarter of 2023 was $14 million, an increase of $10 million year-over-year.